View the EURETINA 2022 symposium on Broadening management options for DME: Recent clinical insights from targeting dual inhibition of Ang-2 and VEGF-A
Targeting additional pathways beyond vascular endothelial growth factor A (VEGF-A) may address treatment challenges in diabetic macular edema (DME) and optimise patient outcomes. In particular, the Angiopoietin (Ang)-Tie pathway shows promise as a novel therapeutic target to address the vascular instability observed in retinal diseases. In this symposium, 4 expert panellists will summarise the impact of dual Ang-2/VEGF-A inhibition, highlight opportunities to improve clinical outcomes in DME, outline preclinical evidence and clinical findings for dual Ang-2/VEGF-A inhibition, and review patient cases for faricimab▼ in the clinic and the real-world.